Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers September 26, 2017
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - September 26, 2017

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

9/26/17 - Lackawanna County files opioid lawsuit against drug companies [The Times-Tribune, Scranton, Pa.]
Sept. 25 Attorneys for Lackawanna County filed a civil lawsuit Monday against 14 drug companies over what county officials see as their role in spawning the opioid epidemic less than a week after another county resident died from an opioid overdose. "Today, we add one more person to the list of Lackawanna County citizens that lost their life t
9/25/17 - "Method of Treating Neuropathic Pain with a Synergistic Pharmaceutical Composition Comprising Palmitoylethanolamide and L-Acetylcarnitine" in Patent...
"Method of Treating Neuropathic Pain with a Synergistic Pharmaceutical Composition Comprising Palmitoylethanolamide and L-Acetylcarnitine" in Patent Application Approval Process. By a News Reporter-Staff News Editor at Pharma Business Week A patent application by the inventors DELLA VALLE, Francesco; DELLA VALLE, Maria Federica, filed on May 24,
9/25/17 - 'Living medicine' cancer therapy starts clinical trials
London- based biopharmaceutical company Autolus is undertaking a novel cancer trial targeting T-cells. The study- which Autolus is calling APRIL- is for its AUTO2 product. Autolus believes that by adding APRIL ligand as a surface protein to the patients T cells it could improve the ability of the body's own immune system to detect and kill cancer c
9/25/17 - Living medicine' cancer therapy starts clinical trials
London- based biopharmaceutical company Autolus is undertaking a novel cancer trial targeting T-cells. The study which Autolus is calling APRIL is for its AUTO2 product. Autolus believes that by adding APRIL ligand as a surface protein to the patients T cells it could improve the ability of the body's own immune system to detect and kill canc
9/25/17 - AbbVie's Upadacitinib ABT-494 Meets All Primary and Ranked Secondary Endpoints in Second Phase 3 Study in Rheumatoid Arthritis
By a News Reporter-Staff News Editor at Clinical Trials Week AbbVie, a global research and development based biopharmaceutical company, announced positive top-line results from the Phase 3 SELECT-BEYOND clinical trial evaluating upadacitinib, an investigational oral JAK1-selective inhibitor, in patients with moderate to severe rheumatoid...
9/25/17 - Acadia Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Sept. 8, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Acadia Pharmaceuticals Inc. was posted on September 8, 2017. The SEC file number is 0001415889-17-001469.. A U.S. Securities and Exchange Commission
9/25/17 - Acadia Pharmaceuticals Inc. Files SEC Form CT ORDER, Confidential Treatment Order: (Sept. 12, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Acadia Pharmaceuticals Inc. was posted on September 12, 2017. The SEC file number is 9999999997-17-008655.. A U.S. Securities and Exchange Commission
9/25/17 - ACCELERON PHARMA INC. (NASDAQ:XLRN) Files An 8-K Other Events
ACCELERON PHARMA INC. (NASDAQ:XLRN) Files An 8-K Other EventsItem 8.01 Other Events. On September20, 2017, Acceleron Pharma Inc. (the Company) entered into an underwriting agreement (the Underwriting Agreement) with J.P. Morgan Securities LLC, Citigroup Global Markets Inc. and Leerink Partners LLC, as representatives (collectively, the
9/25/17 - Acceleron to Host Research and Development Day on September 19, 2017
By a News Reporter-Staff News Editor at Pharma Business Week Acceleron Pharma Inc. announced it will webcast a live presentation from its Research and Development Day on Tuesday, September 19, 2017. The event will take place from 8:00 a.m. to 12:00 p.m. EDT in New York City. Keywords for this news article include: Pharmaceutical Companies, Accele
9/25/17 - Acelrx Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Sept. 11, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Acelrx Pharmaceuticals Inc. was posted on September 11, 2017. The SEC file number is 0001437749-17-015834.. A U.S. Securities and Exchange Commission
9/25/17 - Acer Therapeutics Reports Positive Results From Pivotal Clinical Trial of EDSIVO? (celiprolol) for Treatment of Vascular Ehlers-Danlos Syndrome
Acer Therapeutics Inc.,, a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today announced positive results from the pivotal clinical trial of EDSIVO? for the treatment of vascular Ehlers-Danlos Syndrome. There are curren
9/25/17 - ACORDA THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Acorda Therapeutics, Inc. To Contact The Firm
On August 29, 2017, Acorda announced that it had received a Refusal to File letter from the U.S. Food and Drug Administration, which informed the Company that its New Drug Application for INBRIJA "was not sufficiently complete to permit a substantive review." CONTACT: FARUQI& FARUQI, LLP 685 Third Avenue, 26 th Floor New York, NY 10017 Attn: Richar
9/25/17 - Acura Pharmaceuticals, Inc. Files SEC Form 8-K, Current Report: (Sept. 11, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Acura Pharmaceuticals, Inc. was posted on September 11, 2017. The SEC file number is 0001144204-17-047360.. A U.S. Securities and Exchange Commission
9/25/17 - Adamas Pharmaceuticals Inc. Files SEC Form CT ORDER, Confidential Treatment Order: (Sept. 11, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Adamas Pharmaceuticals Inc. was posted on September 11, 2017. The SEC file number is 9999999997-17-008603.. A U.S. Securities and Exchange Commission
9/25/17 - Advances in Knee Implants, ECG monitoring, Remote Monitoring, Cloud Technology, Disposable Surgical Retractors, and Anti-snoring Devices - Research and Markets
The "Advances in Knee Implants, ECG monitoring, Remote Monitoring, Cloud Technology, Disposable Surgical Retractors, and Anti-snoring Devices" report has been added to Research and Markets' offering. Innovative Personalized Knee Implant Efficient Electrocardiogram Management and Reporting Software Continuous Patient Monitoring Solutions in...
9/25/17 - Aerie Pharmaceuticals Announces Appointment of Sheila Elliott, PharmD, as Western Regional Director of Medical Science Liaisons
Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointment of Sheila Elliott, PharmD, as Western Regional Director of Medical Science Liaisons, reporting to We
9/25/17 - Aeterna Zentaris Announces Appointment of Interim Chief Financial Officer
Aeterna Zentaris Inc. a specialty biopharmaceutical company announced effective today, September 25, 2017, that Jeffrey Whitnell has been appointed to the position of Interim Chief Financial Officer. From April 2010 to March 2015, Mr. Whitnell served as Chief Financial Officer and Controller of Reliefband Medical Technologies, a private equity-back
9/25/17 - Aethlon Medical Receives Expedited Access Pathway Designation from FDA to Accelerate U.S. Access to the Hemopurifier as a Treatment for...
Aethlon Medical Receives Expedited Access Pathway Designation from FDA to Accelerate U.S. Access to the Hemopurifier as a Treatment for Life-Threatening Viruses. By a News Reporter-Staff News Editor at Pharma Business Week Aethlon Medical, Inc., a therapeutic technology company focused on unmet needs in global health and biodefense, announced
9/25/17 - Agile Therapeutics Inc. Files SEC Form 8-K, Current Report: (Sept. 12, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Agile Therapeutics Inc. was posted on September 12, 2017. The SEC file number is 0001104659-17-056769.. A U.S. Securities and Exchange Commission fil
9/25/17 - Agilent Obtains U.S. FDA Approval for GenetiSure Dx Postnatal Assay
By a News Reporter-Staff News Editor at Pharma Business Week Agilent Technologies Inc. has announced that it has obtained 510 clearance from the U.S. Food and Drug Administration for the GenetiSure Dx Postnatal Assay: its first comparative genomic hybridization assay for diagnostic use. Previously available only in Europe, U.S. clinical genetic..
9/25/17 - Agilent Technologies Receives Expanded FDA Approval for the Use of Dako PD-L1 IHC 22C3 pharmDx Companion Diagnostic in Gastric or Gastroesophageal Junction (GEJ) Cancer
SANTA CLARA, Calif. Agilent Technologies Inc. today announced its Dako PD-L1 IHC 22 C3 pharmDx assay has an expanded label approved by U.S. Food and Drug Administration, for use as an aid in identifying gastric or GEJ adenocarcinoma patients for treatment with KEYTRUDA, an anti-PD-1 therapy manufactured by Merck& Co., Inc., Kenilworth, N.J., USA.
9/25/17 - Alastair McEwan Steps Down as Chief Operating Officer of Veloxis Pharmaceuticals AS
Craig Collard, CEO of Veloxis Pharmaceuticals A/S said' We greatly appreciate Alastair's contributions to the Company, including the key role he has played in building the commercial infrastructure for Envarsus XR.'. Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant...
9/25/17 - Aldeyra Therapeutics Announces Positive Results from Dry Eye Disease Phase 2a Clinical Trial
By a News Reporter-Staff News Editor at Clinical Trials Week Aldeyra Therapeutics, Inc., a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, announced positive results from a Phase 2 a clinical trial of topical ocular ADX-102 in patients
9/25/17 - Alexion Pharmaceuticals Inc. Files SEC Form 8-K, Current Report: (Sept. 12, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Alexion Pharmaceuticals Inc. was posted on September 12, 2017. The SEC file number is 0000899866-17-000163.. A U.S. Securities and Exchange Commissio
9/25/17 - Alexion to Host Call to Discuss Restructuring to Advance Corporate Strategy at 8:30 a.m. on September 12, 2017
By a News Reporter-Staff News Editor at Pharma Business Week Alexion Pharmaceuticals announced that the Company will issue a press release on its restructuring to advance its corporate strategy on Tuesday, September 12, 2017 at 8:00 a.m. ET. Following the release, Alexion management will conduct a conference call and audio webcast on Tuesday, Sep
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415